Navigation Links
Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement
Date:5/27/2009

NORCROSS, Ga., May 27 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has signed a five-year agreement with Alverno Clinical Laboratories, LLC, one of the largest regional hospital laboratory integrated delivery systems in the nation, serving 27 hospitals in Illinois and Indiana.

Under the agreement, Alverno is standardizing pre-transfusion testing in 26 facilities with Immucor automation through the acquisition of 24 Echo instruments and 2 Capture Workstations. Additionally, Immucor will be the primary source for Alverno's blood bank reagent needs.

"We are pleased to partner with such an innovative organization as Alverno," stated Dr. Gioacchino De Chirico, President and Chief Executive Officer of Immucor. "We believe that integrated delivery networks can achieve significant benefits both in terms of improving operational efficiency and improving patient safety through standardizing their blood bank operations with Immucor automation."

"Our goal is to produce accurate and timely test results while implementing standardized best practices across all laboratory sites," stated Sam Terese, Chief Operating Officer of Alverno Clinical Laboratories. "We chose Immucor due to the exceptional functionality of the Echo instrument and its fit with LEAN operations as well as Immucor's commitment to improving transfusion medicine."

Immucor's innovative automation strategy provides scalable solutions to meet the needs of all blood banks, regardless of size. Immucor has continually invested in automation since 1998, most recently with the Echo instrument. The Echo, which is designed for smaller volume laboratories, features a broad test menu, instant access and the industry's fastest turnaround times.

About Alverno Clinical Laboratories

Located in Hammond, In., Alverno Clinical Laboratories, LLC is one of the largest regional hospital laboratory integrated delivery systems in the nation. Alverno's operations include a regional core laboratory, 27 hospital laboratories, and a network of patient service centers in both Indiana and Illinois. Alverno is a joint venture of the Sisters of St. Francis Health Services, Inc., Resurrection Health Care and Provena Health. For more information on Alverno, please visit our website at www.alvernoclinicallabs.com.

About Immucor

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Immucor Schedules Second Quarter Earnings Release and Conference Call
2. FDA Accepts Immucors Response to Warning Letter
3. Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance
4. Immucor CEOs Italian Trial Moves Toward Second Phase
5. Immucor To Acquire BioArray Solutions Ltd.
6. Immucor Responding to FTC Inquiry
7. Immucor Settles SEC Investigation
8. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
9. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
10. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
11. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 2016 Strasbourg, France , ... --> Strasbourg, France , to the US ... is pleased to announce that it acted as an advisor ... in Strasbourg, France , to the US ... --> Transgene (Euronext: TNG), a member of ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):